Please login to the form below

Not currently logged in
Email:
Password:

Kymab appoints its first chief medical officer

Dr Sonia Quaratino joins the firm from Novartis

Sonia QuaratinoKymab has appointed Dr Sonia Quaratino as its chief medical officer - a newly created role that will see her manage clinical development of the group’s expanding therapeutic antibody portfolio.

She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.

Dr Quaratino said: “Kymab’s emerging human antibody pipeline provides great potential to improve patient treatment options in our four main therapeutics areas of focus."

She previous served Novartis as its global clinical programme leader, transitional clinical oncology, with responsibility for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology.

Prior to her time at Novartis, Quaratino worked for Merck Serono, where she was responsible for the clinical development of various immunomodulators.

Dr David Chiswell, CEO of Kymab, said: “I am delighted to welcome Sonia to Kymab. With her track demonstrated track record in clinical development and medical affairs, Sonia is a superb addition to Kymab’s management team as we prepare for our first clinical trials.

“Sonia’s deep understanding of the global environment in clinical research compliment those of Dr Arndt Schottelius, our new executive VP of R&D. These two key appointments add high calibre of depth and provide further validation to our burgeoning and advancing R&D pipeline.”

10th May 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics